![Author ORCID: We display the ORCID iD icon alongside authors names on our website to acknowledge that the ORCiD has been authenticated when entered by the user. To view the users ORCiD record click the icon. [opens in a new tab]](https://chemrxiv.org/engage/assets/public/chemrxiv/images/logos/orcid.png)
Abstract
The World Health Organization (WHO) has declared a pandemic of the 2019 novel cornavirus SARS-CoV-2 infection (COVID-19). There is, however, no confirmed anti-COVID-19 therapeutic currently. In order to assist structure-based discovery of repurposing drugs against this disease, knowledge-based models of SARS-CoV-2 proteins were constructed using MODELLER software, and their models were refined by PHENIX and COOT. The model quality was assessed with MolProbity. The ligand molecules in the template structures were compared with approved/experimental drugs and components of natural medicines from the KEGG and KNApSAcK databases. The models suggested several drugs, such as carfilzomib, sinefungin, tecadenoson, and trabodenoson, as potential drugs for COVID-19.
